Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis
PaperCitations, authors & open-access status
Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 26 citations, 2025 year and green oa status.
26
Citations
2025
Year
green
OA Status